[EN] 1, 2, 5-THIADIAZOLIDIN-3-ONE 1, 1 DIOXIDE DERIVATIVES AS INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE PTP1B [FR] DERIVES DE 1, 2, 5-THIADIAZOLIDIN-3-ONE 1, 1 DIOXYDE UTILISES EN TANT QU'INHIBITEURS DE LA PROTEINE TYROSINE PHOSPHATASE PTP1B
Design, synthesis and evaluation of novel diaryl urea derivatives as potential antitumor agents
摘要:
A novel series of diaryl ureas containing different linker groups were designed and synthesized. Their in vitro antitumor activity against MX-1, A375, HepG2, Ketr3 and HT-29 was evaluated using the standard MIT assay. Compounds having a rigid linker group such as vinyl, ethynyl and phenyl showed significant inhibitory activity against a variety of cancer cell lines. Specifically, compound 23 with a phenyl linker group demonstrated broad-spectrum antitumor activity with IC50 values of 5.17-6.46 mu M against five tested tumor cell lines. Compound 23 is more potent than reference drug sorafenib (8.27-15.2 mu M), representing a promising lead for further optimization. (C) 2014 Elsevier Masson SAS. All rights reserved.
Exploiting the Carboxylate-Binding Pocket of β-Lactamase Enzymes Using a Focused DNA-Encoded Chemical Library
作者:Suhyeorn Park、Jiayi Fan、Srinivas Chamakuri、Murugesan Palaniappan、Kiran Sharma、Xuan Qin、Jian Wang、Zhi Tan、Allison Judge、Liya Hu、Banumathi Sankaran、Feng Li、B. V. Venkataram Prasad、Martin M. Matzuk、Timothy Palzkill
DOI:10.1021/acs.jmedchem.3c01834
日期:2024.1.11
resistance to the important β-lactam class of antibiotics. The OXA-48 and NDM-1 β-lactamases cause resistance to the last-resort β-lactams, carbapenems, leading to a serious public health threat. Here, we utilized DNA-encoded chemical library (DECL) technology to discover novel β-lactamase inhibitors. We exploited the β-lactamase enzyme–substrate binding interactions and created a DECL targeting the carboxylate-binding
METHODS AND COMPOSITIONS FOR PREVENTING SKIN TOXICITIES CAUSED BY BIOLOGICAL TARGETED CANCER DRUGS
申请人:Hadasit Medical Research Services
and Development Ltd.
公开号:EP4013408A1
公开(公告)日:2022-06-22
[EN] METHODS AND COMPOSITIONS FOR PREVENTING SKIN TOXICITIES CAUSED BY BIOLOGICAL TARGETED CANCER DRUGS<br/>[FR] PROCÉDÉS ET COMPOSITIONS POUR PRÉVENIR LES TOXICITÉS CUTANÉES PROVOQUÉES PAR DES MÉDICAMENTS ANTICANCÉREUX CIBLÉS BIOLOGIQUES
申请人:HADASIT MEDICAL RES SERVICES & DEVELOPMENT LIMITED
公开号:WO2021028919A1
公开(公告)日:2021-02-18
The invention concerns methods for inhibiting binding of systemically administered drugs to a target in the skin by topically administering materials prior to or concomitantly with administration of the systemic drugs.